Sagimet Biosciences Inc. - Series A

As of June 30, 2026, Sagimet Biosciences Inc. Class A carries a market capitalization of 417.65M, placing it among publicly traded companies globally. Its enterprise value stands at 209.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sagimet Biosciences Inc. Class A's next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Sagimet Biosciences Inc. Class A has 61.78M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Sagimet Biosciences Inc. Class A maintains a current ratio of 45.02, meaning it holds 45.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Sagimet Biosciences Inc. Class A posted a negative return on equity (ROE) of -24.37, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -23.49, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 15.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Sagimet Biosciences Inc. Class A's stock has gained approximately 36.87% over the past 52 weeks. The 50-day moving average sits at 8.72, while the 200-day moving average is 6.42.

Over the twelve months ended June 30, 2026, Sagimet Biosciences Inc. Class A generated - - in revenue and converted that into -41.21M in net income, yielding earnings per share of -1.09. EBITDA reached -46.07M, while operating income came in at -46.07M.

As of June 30, 2026, Sagimet Biosciences Inc. Class A holds 210.18M in cash and equivalents against 1.70M in total debt, resulting in a net debt position of -145.21M. Total book value stands at 224.21M, with working capital of 208.82M providing operational flexibility.

Sagimet Biosciences Inc. Class A produced -36.52M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -14.34: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

As of June 30, 2026, Sagimet Biosciences Inc. Class A has an Altman Z-Score of 37.81, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.